These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 30602016)
1. Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen. van Velzen DM; Paldino A; Klaver M; Nota NM; Defreyne J; Hovingh GK; Thijs A; Simsek S; T'Sjoen G; den Heijer M J Clin Endocrinol Metab; 2019 Jun; 104(6):1937-1947. PubMed ID: 30602016 [TBL] [Abstract][Full Text] [Related]
2. Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen. Vlot MC; Wiepjes CM; de Jongh RT; T'Sjoen G; Heijboer AC; den Heijer M J Bone Miner Res; 2019 Oct; 34(10):1862-1872. PubMed ID: 31099910 [TBL] [Abstract][Full Text] [Related]
3. Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria. Meyer G; Mayer M; Mondorf A; Flügel AK; Herrmann E; Bojunga J Eur J Endocrinol; 2020 Feb; 182(2):149-156. PubMed ID: 31751300 [TBL] [Abstract][Full Text] [Related]
4. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). Cocchetti C; Castellini G; Iacuaniello D; Romani A; Maggi M; Vignozzi L; Schreiner T; den Heijer M; T'Sjoen G; Fisher AD J Sex Med; 2021 Apr; 18(4):821-829. PubMed ID: 33745831 [TBL] [Abstract][Full Text] [Related]
5. Changes of Vitamin D-Binding Protein, and Total, Bioavailable, and Free 25-Hydroxyvitamin D in Transgender People. Chen H; Wiepjes CM; van Schoor NM; Heijboer AC; de Jongh RT; den Heijer M; Lips P J Clin Endocrinol Metab; 2019 Jul; 104(7):2728-2734. PubMed ID: 30785996 [TBL] [Abstract][Full Text] [Related]
6. Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate). Alwers R; Urdinola J; Onatra W; Sánchez F; Posso H Maturitas; 1999 May; 32(1):41-50. PubMed ID: 10423715 [TBL] [Abstract][Full Text] [Related]
7. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Godsland IF Fertil Steril; 2001 May; 75(5):898-915. PubMed ID: 11334901 [TBL] [Abstract][Full Text] [Related]
8. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study. Kuijpers SME; Wiepjes CM; Conemans EB; Fisher AD; T'Sjoen G; den Heijer M J Clin Endocrinol Metab; 2021 Sep; 106(10):e3936-e3945. PubMed ID: 34125226 [TBL] [Abstract][Full Text] [Related]
9. Variation in sensitivity and rate of change in body composition: steps toward individualizing transgender care. van Velzen DM; Nota NM; Simsek S; Conemans EB; T'Sjoen G; den Heijer M Eur J Endocrinol; 2020 Nov; 183(5):529-536. PubMed ID: 33071222 [TBL] [Abstract][Full Text] [Related]
10. Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment: A Multicenter Prospective Observational Study. Wiepjes CM; Vlot MC; Klaver M; Nota NM; de Blok CJ; de Jongh RT; Lips P; Heijboer AC; Fisher AD; Schreiner T; T'Sjoen G; den Heijer M J Bone Miner Res; 2017 Jun; 32(6):1252-1260. PubMed ID: 28370342 [TBL] [Abstract][Full Text] [Related]
11. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Falsetti L; Pasinetti E Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434 [TBL] [Abstract][Full Text] [Related]
12. Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study. Muir CA; Guttman-Jones M; Man EJ Endocrine; 2024 Jul; 85(1):370-379. PubMed ID: 38386168 [TBL] [Abstract][Full Text] [Related]
13. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen. Gava G; Mancini I; Alvisi S; Seracchioli R; Meriggiola MC Eur J Endocrinol; 2020 Dec; 183(6):561-569. PubMed ID: 33055297 [TBL] [Abstract][Full Text] [Related]
14. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. Chen FP; Lee N; Soong YK; Huang KE Menopause; 2001; 8(5):347-52. PubMed ID: 11528361 [TBL] [Abstract][Full Text] [Related]
15. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032 [TBL] [Abstract][Full Text] [Related]
16. Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen. Scheres LJJ; Selier NLD; Nota NM; van Diemen JJK; Cannegieter SC; den Heijer M J Thromb Haemost; 2021 Apr; 19(4):1029-1037. PubMed ID: 33527671 [TBL] [Abstract][Full Text] [Related]
17. Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment. Dobrolińska M; van der Tuuk K; Vink P; van den Berg M; Schuringa A; Monroy-Gonzalez AG; García DV; Schultz WCMW; Slart RHJA J Sex Med; 2019 Sep; 16(9):1469-1477. PubMed ID: 31326306 [TBL] [Abstract][Full Text] [Related]
18. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism. Schram JH; Boerrigter PJ; The TY Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480 [TBL] [Abstract][Full Text] [Related]
19. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. Gava G; Cerpolini S; Martelli V; Battista G; Seracchioli R; Meriggiola MC Clin Endocrinol (Oxf); 2016 Aug; 85(2):239-46. PubMed ID: 26932202 [TBL] [Abstract][Full Text] [Related]
20. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Mastorakos G; Koliopoulos C; Creatsas G Fertil Steril; 2002 May; 77(5):919-27. PubMed ID: 12009344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]